Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma - Episode 9
ASCO 2025 Insights: CARTITUDE-1–– Long-Term Follow-Up
Panelists discuss how 5-year follow-up data from the CARTITUDE-1 trial demonstrate durable responses and potential functional cures in a subset of relapsed/refractory myeloma patients treated with cilta-cel.
Five-Year Data From CARTITUDE-1 and Long-Term Survivors
Five-year follow-up data from the CARTITUDE-1 trial reveals that approximately one-third of patients treated with cilta-cel remain progression-free and off therapy, a remarkable result in the relapsed/refractory setting.
These findings challenge the historic notion that multiple myeloma is uniformly incurable, suggesting the possibility of long-term remission in a subset of patients. Importantly, no new safety signals or CAR T–related toxicities were reported, underscoring the durability and tolerability of cilta-cel.
The sustained responses in heavily pretreated patients highlight the potential for earlier use of CAR T therapies to further improve outcomes. These data provide a compelling rationale for rethinking sequencing strategies and potentially redefining cure in myeloma.
Related Content:
